Synergistic cytotoxic effect of genistein and doxorubicin on drug-resistant human breast cancer MCF-7/Adr cells

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1647-1653

  Xue, Jia Peng ^a   Wang, Geng ^a   Zhao, Zong Bin ^a   Wang, Qun ^a   Shi, Yun ^a  

^a Taihe Hospital   (China)

Author keywords

Doxorubicin; Genistein; MCF 7 Adr; Reversal of multidrug resistance

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENISTEIN; GLYCOPROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE ARREST; CELL LEVEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADENOCARCINOMA; BREAST TUMOR; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENETICS; METABOLISM;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; GENISTEIN; HUMANS; MCF-7 CELLS; P-GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 84916619262     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3365     Document Type: Article

References (42)

1. Trapé AP and Gonzalez-Angulo AM: Breast cancer and metastasis: on the way toward individualized therapy. Cancer Genomics Proteomics 9: 297-310, 2012.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Harbeck N: Never too late: reducing late breast cancer relapse risk. Curr Med Res Opin 24: 3295-3305, 2008.
4. Simstein R, Burow M, Parker A, Weldon C and Beckman B: Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228: 995-1003, 2003. (Pubitemid 37222167)
5. Payne KK and Manjili MH: Adaptive immune responses associated with breast cancer relapse. Arch Immunol Ther Exp 60: 345-350, 2012.
6. Joerger M and Thürlimann B: Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 13: 165-178, 2013.
7. Redden MH and Fuhrman GM: Neoadjuvant chemotherapy in the treatment of breast cancer. Surg Clin North Am 93: 493-499, 2013.
8. Fuksa L, Micuda S, Grim J, Ryska A and Hornychova H: Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. Cancer Invest 30: 663-678, 2012.
9. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670-686, 1992.
10. Prados J, Melguizo C, Ortiz R, et al : Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem 12: 1058-1070, 2012.
11. Brunello A, Roma A, Falci C and Basso U: Chemotherapy and targeted agents for elderly women with advanced breast cancer. Recent Pat Anticancer Drug Discov 3: 187-201, 2008.
12. Alm El-Din MA, El-Badawy SA and Taghian AG: Breast cancer after treatment of Hodgkin's lymphoma: general review. Int J Radiat Oncol Biol Phys 72: 1291-1297, 2008.
13. Khalil MY, Mapa M, Shin HJ and Shin DM: Advances in the management of malignant mesothelioma. Curr Oncol Rep 5: 334-341, 2003. (Pubitemid 38898801)
14. Giai M, Biglia N and Sismondi P: Chemoresistance in breast tumors. Eur J Gynaecol Oncol 12: 359-373, 1991.
15. Sakamoto T, Horiguchi H, Oguma E and Kayama F: Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor- positive breast cancer cells. J Nutr Biochem 21: 856-864, 2010
16. de Lemos ML: Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 35: 1118-1121, 2001.
17. Usui T: Pharmaceutical prospects of phytoestrogens. Endocr J 53: 7-20, 2006.
18. Sarkar FH, Adsule S, Padhye S, Kulkarni S and Li Y: The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev Med Chem 6: 401-407, 2006.
19. Ravindranath MH, Muthugounder S, Presser N and Viswanathan S: Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121-165, 2004. (Pubitemid 40103418)
20. Kanagasabai R, Krishnamurthy K, Druhan LJ and Ilangovan G: Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in adriamycin-resistant human breast cancer cells. J Biol Chem 286: 33289-33300, 2011.
21. Lu L, Zhou D, Jiang X, Song K, Li K and Ding W: Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci 16: 1271-1279, 2012.
22. Zhang HC, Zhang F, Wu B, et al: Identification of the interaction between P-glycoprotein and Anxa2 in multidrug-resistant human breast cancer cells. Cancer Biol Med 9: 99-104, 2012.
23. Gampenrieder SP, Rinnerthaler G and Greil R: Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol 2013: 732047, 2013.
24. Steward WP and Brown K: Cancer chemoprevention: a rapidly evolving field. Br J Cancer 109: 1-7, 2013.
25. Bartlett J, Canney P, Campbell A, et al: Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin Oncol 25: 109-116, 2013.
26. Loo TW and Clarke DM: Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277: 44332-44338, 2002. (Pubitemid 36157868)
27. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9: 1266-1272, 2002. (Pubitemid 35331774)
28. Menard S, Pupa SM, Campiglio M and Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578, 2003. (Pubitemid 37372337)
29. Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett 269: 226-242, 2008.
30. Tarkowski M, Kokocinska M and Latocha M: Genistein in chemoprevention and treatment. Pol Merkur Lekarski 34: 54-57, 2013 (In Polish).
31. Swami S, Krishnan AV, Peehl DM and Feldman D: Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 241: 49-61, 2005. (Pubitemid 41262171)
32. Yu Z, Tang Y, Hu D and Li J: Inhibitory effect of genistein on mouse colon cancer MC-26 cells involved TGF-beta1/Smad pathway. Biochem Biophys Res Commun 333: 827-832, 2005. (Pubitemid 40854233)
33. Pabona JM, Dave B, Su Y, et al: The soybean peptide lunasin promotes apoptosis of mammary epithelial cells via induction of tumor suppressor PTEN: similarities and distinct actions from soy isoflavone genistein. Genes Nutr 8: 79-90, 2013.
34. Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF and De Luo B: Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Mol Biol Rep 39: 4971-4979, 2012.
35. Tacar O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65: 157-170, 2013.
36. Liu Y, Du F, Chen W, Yao M, Lv K and Fu P: Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp Cell Res 319: 3140-3149, 2013.
37. Shi R, Peng H, Yuan X, et al: Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. J Cell Biochem 114: 1890-1900, 2013.
38. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985. (Pubitemid 16169997)
39. Harari D and Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19: 6102-6114, 2000. (Pubitemid 32059460)
40. Seo HS, Choi HS, Choi HS, et al: Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer Res 31: 3301-3313, 2011.
41. Choi EJ and Kim GH: Antiproliferative activity of daidzein and genistein may be related to ERα/c-erbB-2 expression in human breast cancer cells. Mol Med Rep 7: 781-784, 2013.
42. Mai Z, Blackburn GL and Zhou JR: Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptorpositive and HER2-overexpressing human breast cancer cells. Mol Carcinog 46: 534-542, 2007. (Pubitemid 47068072)